Mr. William Edward Holt Jr., R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 30508 Ardmore Ave, Ardmore, AL 35739 Phone: 256-423-2155 Fax: 256-423-8999 |
Ms. Annie Hogan Allen, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 30508 Ardmore Ave, Ardmore, AL 35739 Phone: 256-423-2155 |
Joseph William Harris, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 30508 Ardmore Ave, Ardmore, AL 35739 Phone: 256-423-2155 |
Mr. Jason Edwin Murph, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 29930 Ardmore Ave, Ardmore, AL 35739 Phone: 256-423-8989 Fax: 256-423-8990 |
Nick W Holland, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 30508 Ardmore Ave, Ardmore, AL 35739 Phone: 256-423-2155 Fax: 256-423-8999 |
News Archive
In a clinical trial involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers at the University of Colorado Anschutz Medical Campus and fellow scientists around the world have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke.
In a continuing effort to educate prescribers and patients about the potential risks related to opioid use, the U.S. Food and Drug Administration today announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death.
Research conducted by a team of Norton Thoracic Institute scientists on a novel therapeutic avenue for an aggressive and difficult to treat subgroup of lung cancer was published in the August 15, 2017 issue of Cancer Research.
Researchers from Syracuse, New York, report a new, highly accurate, neuromonitoring method that can be used during thoracic spine surgery to prevent malpositioning of pedicle screws such that they enter the spinal canal and possibly cause postoperative neurological impairment.
The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.
› Verified 4 days ago